Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
The Gaithersburg, Maryland-based company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.
LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
Quanterix intends to grant underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock at the public offering price.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
Researchers generated a spatial transcriptome of mouse embryonic germ layer tissues from the pre-gastrulation stage to the late gastrulation stage.
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
The company attributed the revenue decline to a 96 percent drop in licensing revenues, which more than offset a 36 percent increase in product sales.
Ontera, formerly called Two Pore Guys, was founded to develop a handheld molecular sensor based on proprietary solid-state nanopore technology.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
Revenues from product and product-related services more than doubled to $4.4 million, but collaborative development revenues sank 52 percent to $1.4 million.
The San Francisco-based medical genetics firm generated $53.5 million in revenues in the second quarter, beating analysts' consensus estimate of $50.7 million.
The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.
The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.
By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.
The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.
The firm noted that in the quarter, the US Food and Drug Administration granted Breakthrough Device designation for its exosome-based liquid biopsy test.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
Revenues were in line with Wall Street estimates, and revenue growth represented strength across all three of the firm's business segments.
Driving the revenue increase was a 187 percent year-over-year rise in the number of billable tests the company delivered during the quarter.
The company posted Q2 revenues of $13.5 million, up from $8.6 million in Q2 2018 and above the consensus Wall Street estimate of $11.5 million.
The Carlsbad, California-based molecular diagnostics firms reported $18.4 million in revenues, up from 14.9 million in Q2 of 2018.
The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
As part of the agreement, Kindstar will use InCellDx's single-cell immuno-oncology and oncology diagnostic products in China, including Hong Kong and Macao.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.